Cell therapies including chimeric antigen receptor (CAR) T-cell therapy represent novel treatments for patients with lymphoma, especially for those who have progressed on existing chemotherapy or autologous hematopoietic stem-cell transplantation (ASCT). CAR T-cell therapy involves modified immune cells from the patient to attack the cancer and there are currently five approved by the FDA: idecabtagene vicleucel, lisocabtagene maraleucel, tisagenlecleucel, brexucabtagene autoleucel, and axicabtagene ciloleucel.

In this exclusive podcast, Yi Lin, MD, PhD, Mayo Clinic, Rochester, MN, Krish Patel, MD, Swedish Cancer Institute, Seattle, WA, Nathan Fowler, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, Michael Bishop, MD, University of Chicago, Chicago, IL, and Stephen Ansell, MD, PhD, Mayo Clinic, Rochester, MN, discuss important data from the ELARA (NCT03568461) and BELINDA (NCT03570892) trials, NK cell therapies, and the role of cell therapies in treating lymphoma. This interview took place at the 63rd ASH Annual Meeting and Exposition Congress, Atlanta, GA, 2021.